Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: wpckr who wrote (735)	9/14/1998 11:46:00 AM
From: Hong-Lee Yu	Read Replies (2) \| Respond to of 1686

All, Both Lehman and Bear Stern made positive comments and raised the price (in addition to Goldman Sache, PW, HQ) Lehman: Increase Avonex sales projections this Q to 102M from 95M, 377M (in 98') from 370M. Raised 0.44 3Q EPS to 0.49Q, 1.78 98' EPS to 1.80, $2.36 99' to $2.43. Potential catalysts from within remainder of co's pipeline as efficacy data over next 6-12 months. Has $65 target. Bear Stern: Saying Biogen's strategy has been to hit the consensus estimates and has resulted in Co's underreporting EPS by accelerating expenses and deferring revenues. Believe that Co will be unable to hold back EPS for remainder of years. Believe Avonex sales will exceed Street estimates by significant amount for remainder of 98'. Has $70 target. My guess is that analysts are going to raise the estimates again after Q3. Even bear Stern's $2.59 for 99' might be too conservative.